MX2018004050A - Inhibidores marcados con 18f mejorados del antigeno prostatico especifico de membrana (psma) y su uso como agentes de formacion de imagenes para el cancer de prostata. - Google Patents
Inhibidores marcados con 18f mejorados del antigeno prostatico especifico de membrana (psma) y su uso como agentes de formacion de imagenes para el cancer de prostata.Info
- Publication number
- MX2018004050A MX2018004050A MX2018004050A MX2018004050A MX2018004050A MX 2018004050 A MX2018004050 A MX 2018004050A MX 2018004050 A MX2018004050 A MX 2018004050A MX 2018004050 A MX2018004050 A MX 2018004050A MX 2018004050 A MX2018004050 A MX 2018004050A
- Authority
- MX
- Mexico
- Prior art keywords
- psma
- improved
- image formation
- specific antigen
- prostata cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- G01N33/57555—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere en general al campo de los productos radiofarmacéuticos y a su uso en medicina nuclear como marcadores y agentes de formación de imágenes para diversos estados patológicos de cáncer de próstata.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15002800 | 2015-09-30 | ||
| EP16164090 | 2016-04-06 | ||
| EP16182764 | 2016-08-04 | ||
| PCT/EP2016/001573 WO2017054907A1 (en) | 2015-09-30 | 2016-09-19 | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018004050A true MX2018004050A (es) | 2018-08-01 |
| MX390931B MX390931B (es) | 2025-03-21 |
Family
ID=57121178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004050A MX390931B (es) | 2015-09-30 | 2016-09-19 | Inhibidores marcados con 18f mejorados del antígeno prostático específico de membrana (psma) y su uso como agentes de formación de imágenes para el cáncer de próstata. |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10815200B2 (es) |
| EP (2) | EP3805250A1 (es) |
| JP (1) | JP6824971B2 (es) |
| KR (1) | KR102233726B1 (es) |
| CN (1) | CN108026144B (es) |
| AU (1) | AU2016333334B2 (es) |
| BR (1) | BR112018005899A2 (es) |
| CL (1) | CL2018000604A1 (es) |
| CO (1) | CO2018003726A2 (es) |
| CU (1) | CU24524B1 (es) |
| CY (1) | CY1123790T1 (es) |
| DK (1) | DK3356385T3 (es) |
| EA (1) | EA037512B1 (es) |
| ES (1) | ES2844586T3 (es) |
| GE (2) | GEAP202014748A (es) |
| HR (1) | HRP20210183T1 (es) |
| HU (1) | HUE053064T2 (es) |
| IL (1) | IL258378B (es) |
| LT (1) | LT3356385T (es) |
| MX (1) | MX390931B (es) |
| MY (1) | MY197061A (es) |
| NZ (1) | NZ739770A (es) |
| PE (1) | PE20181350A1 (es) |
| PH (1) | PH12018500701B1 (es) |
| PL (1) | PL3356385T3 (es) |
| RS (1) | RS61394B1 (es) |
| SA (1) | SA518391121B1 (es) |
| SI (1) | SI3356385T1 (es) |
| TN (1) | TN2018000089A1 (es) |
| WO (1) | WO2017054907A1 (es) |
| ZA (1) | ZA201801024B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017054907A1 (en) * | 2015-09-30 | 2017-04-06 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer |
| CN109803973B (zh) | 2016-08-10 | 2022-05-24 | 癌靶技术有限责任公司 | 螯合psma抑制剂 |
| ES3041039T3 (en) | 2016-10-27 | 2025-11-06 | Progenics Pharm Inc | Network for medical image analysis, decision support system, and related graphical user interface (gui) applications |
| DE102016122273B4 (de) | 2016-11-18 | 2018-06-21 | Abx Advanced Biochemical Compounds Gmbh | Präkursoren für die Radiofluorierung |
| CA3043619A1 (en) * | 2016-11-23 | 2018-05-31 | Cancer Targeted Technology Llc | Albumin-binding psma inhibitors |
| EP4564288A3 (en) | 2019-04-24 | 2025-09-17 | Progenics Pharmaceuticals, Inc. | Systems and methods for automated and interactive analysis of bone scan images for detection of metastases |
| CN110272468B (zh) * | 2019-05-14 | 2020-12-08 | 上海益泰医药科技有限公司 | 一种前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用 |
| US12417533B2 (en) | 2019-09-27 | 2025-09-16 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| CN111253465A (zh) * | 2020-03-03 | 2020-06-09 | 复旦大学附属肿瘤医院 | 一种psma结合剂及其用途 |
| WO2022167681A1 (en) | 2021-02-08 | 2022-08-11 | Stichting Radboud Universitair Medisch Centrum | Psma-targeting ligands for multimodal applications |
| CN118265718A (zh) * | 2021-07-30 | 2024-06-28 | 国立大学法人大阪大学 | 放射性标记化合物及其用途 |
| JP2024532475A (ja) * | 2021-09-01 | 2024-09-05 | 天津恒瑞医薬有限公司 | 前立腺特異的膜抗原の阻害剤及びその医薬的使用 |
| CN118344391A (zh) * | 2023-01-13 | 2024-07-16 | 浙江普利药业有限公司 | 一种新的用于硼中子捕获疗法的含硼化合物 |
| WO2025041103A1 (en) * | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Psma targeting ligands and methods of use |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5095050B2 (ja) | 1999-04-28 | 2012-12-12 | ジョージタウン ユニバーシティー | 代謝調節型グルタミン酸受容体のリガンド、及び、ＮＡＡＬＡＤａｓｅの阻害剤 |
| EP1409017A4 (en) | 2001-06-25 | 2006-05-24 | Drug Innovation & Design Inc | CELL TARGETING INVOLVING THE RECONNAISSANCE OF EXPONENTIAL FORMS, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS |
| EP1472541B1 (en) | 2002-01-10 | 2009-09-16 | The Johns Hopkins University | Imaging agents and methods of imaging naaladase of psma |
| WO2006093991A1 (en) | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
| EP2087337A4 (en) | 2006-11-03 | 2010-09-08 | Purdue Research Foundation | METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY |
| CN103922998A (zh) | 2006-11-08 | 2014-07-16 | 分子制药洞察公司 | 谷氨酸的异质二聚体 |
| WO2008088648A2 (en) | 2007-01-11 | 2008-07-24 | Immunomedics, Inc. | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules |
| US9044468B2 (en) | 2007-06-26 | 2015-06-02 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents |
| NZ583931A (en) * | 2007-08-17 | 2012-06-29 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| EP2644594B1 (en) | 2007-09-28 | 2017-08-23 | Pfizer Inc | Cancer Cell Targeting Using Nanoparticles |
| WO2009070302A1 (en) | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
| US8562945B2 (en) | 2008-01-09 | 2013-10-22 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof |
| JP2011509304A (ja) | 2008-01-09 | 2011-03-24 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 炭酸脱水酵素ｉｘの阻害剤 |
| DK3222615T3 (da) | 2008-08-01 | 2022-06-20 | Univ Johns Hopkins | Psma-bindende stoffer og anvendelser deraf |
| AU2009322171A1 (en) | 2008-12-05 | 2011-06-30 | Molecular Insight Pharmaceuticals, Inc. | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer |
| HUE068042T2 (hu) | 2009-03-19 | 2024-12-28 | Univ Johns Hopkins | PSMA-targetáló vegyületek és alkalmazásaik |
| GB0905438D0 (en) | 2009-03-30 | 2009-05-13 | Ge Healthcare Ltd | Radiolabelling reagents and methods |
| EP2338892A1 (en) * | 2009-12-18 | 2011-06-29 | Bayer Schering Pharma Aktiengesellschaft | Prostate specific membrane antigen inhibitors |
| GB201020314D0 (en) | 2010-12-01 | 2011-01-12 | Ge Healthcare Ltd | Apoptosis pet imaging agents |
| US9687572B2 (en) | 2010-12-06 | 2017-06-27 | Molecular Insight Pharmaceuticals, Inc. | PSMA-targeted dendrimers |
| WO2012166923A2 (en) | 2011-05-31 | 2012-12-06 | Bind Biosciences | Drug loaded polymeric nanoparticles and methods of making and using same |
| US8926944B2 (en) | 2011-08-05 | 2015-01-06 | Molecular Insight Pharmaceuticals | Radiolabeled prostate specific membrane antigen inhibitors |
| WO2013028664A1 (en) * | 2011-08-22 | 2013-02-28 | Siemens Medical Solutions Usa, Inc. | Psma imaging agents |
| AU2013369982B2 (en) | 2012-12-28 | 2016-11-17 | Tva (Abc), Llc | Targeted conjugates encapsulated in particles and formulations thereof |
| EP2958596B1 (en) | 2013-02-15 | 2019-12-04 | Case Western Reserve University | Psma ligands and uses thereof |
| WO2015004029A1 (en) | 2013-07-08 | 2015-01-15 | Technische Universität München | 18f-labeling of aromatic and heteroaromatic molecules with unprotected carboxylic acid groups |
| US10406246B2 (en) * | 2013-10-17 | 2019-09-10 | Deutsches Kresbsforschungszentrum | Double-labeled probe for molecular imaging and use thereof |
| US20150110814A1 (en) | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| TN2016000137A1 (en) | 2013-10-18 | 2017-10-06 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer. |
| ES3013992T3 (en) | 2013-11-14 | 2025-04-16 | Endocyte Inc | Compounds for positron emission tomography |
| US11124845B2 (en) | 2014-03-18 | 2021-09-21 | The Johns Hopkins University | PSMA-based molecular-genetic reporter system |
| EP3536345A1 (en) | 2014-05-06 | 2019-09-11 | The Johns Hopkins University | Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy |
| WO2016030329A1 (en) | 2014-08-24 | 2016-03-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
| WO2016040179A1 (en) | 2014-09-08 | 2016-03-17 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in psma-targeted radionuclide therapy of prostate cancer |
| EP3209336B1 (en) * | 2014-10-20 | 2019-12-11 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP3011976A1 (en) | 2014-10-20 | 2016-04-27 | Deutsches Krebsforschungszentrum | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents |
| US10736974B2 (en) | 2014-10-22 | 2020-08-11 | The Johns Hopkins University | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy |
| WO2017054907A1 (en) * | 2015-09-30 | 2017-04-06 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer |
-
2016
- 2016-09-19 WO PCT/EP2016/001573 patent/WO2017054907A1/en not_active Ceased
- 2016-09-19 BR BR112018005899-8A patent/BR112018005899A2/pt active Search and Examination
- 2016-09-19 JP JP2018516512A patent/JP6824971B2/ja active Active
- 2016-09-19 MX MX2018004050A patent/MX390931B/es unknown
- 2016-09-19 KR KR1020187012228A patent/KR102233726B1/ko active Active
- 2016-09-19 EA EA201890282A patent/EA037512B1/ru unknown
- 2016-09-19 CN CN201680054882.7A patent/CN108026144B/zh active Active
- 2016-09-19 LT LTEP16778680.5T patent/LT3356385T/lt unknown
- 2016-09-19 MY MYPI2018700586A patent/MY197061A/en unknown
- 2016-09-19 NZ NZ739770A patent/NZ739770A/en unknown
- 2016-09-19 RS RS20210120A patent/RS61394B1/sr unknown
- 2016-09-19 CU CU2018000030A patent/CU24524B1/es unknown
- 2016-09-19 AU AU2016333334A patent/AU2016333334B2/en active Active
- 2016-09-19 EP EP20206516.5A patent/EP3805250A1/en active Pending
- 2016-09-19 PH PH1/2018/500701A patent/PH12018500701B1/en unknown
- 2016-09-19 HR HRP20210183TT patent/HRP20210183T1/hr unknown
- 2016-09-19 DK DK16778680.5T patent/DK3356385T3/da active
- 2016-09-19 PE PE2018000482A patent/PE20181350A1/es unknown
- 2016-09-19 ES ES16778680T patent/ES2844586T3/es active Active
- 2016-09-19 HU HUE16778680A patent/HUE053064T2/hu unknown
- 2016-09-19 EP EP16778680.5A patent/EP3356385B1/en active Active
- 2016-09-19 GE GEAP202014748A patent/GEAP202014748A/en unknown
- 2016-09-19 SI SI201631064T patent/SI3356385T1/sl unknown
- 2016-09-19 GE GEAP201614748A patent/GEP20207106B/en unknown
- 2016-09-19 TN TNP/2018/000089A patent/TN2018000089A1/en unknown
- 2016-09-19 PL PL16778680T patent/PL3356385T3/pl unknown
-
2018
- 2018-02-14 ZA ZA2018/01024A patent/ZA201801024B/en unknown
- 2018-03-08 US US15/915,978 patent/US10815200B2/en active Active
- 2018-03-08 CL CL2018000604A patent/CL2018000604A1/es unknown
- 2018-03-15 SA SA518391121A patent/SA518391121B1/ar unknown
- 2018-03-26 IL IL258378A patent/IL258378B/en active IP Right Grant
- 2018-04-06 CO CONC2018/0003726A patent/CO2018003726A2/es unknown
-
2020
- 2020-10-23 US US17/079,013 patent/US20210053922A1/en not_active Abandoned
-
2021
- 2021-02-01 CY CY20211100081T patent/CY1123790T1/el unknown
-
2023
- 2023-03-17 US US18/186,043 patent/US12054458B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018004050A (es) | Inhibidores marcados con 18f mejorados del antigeno prostatico especifico de membrana (psma) y su uso como agentes de formacion de imagenes para el cancer de prostata. | |
| MY194484A (en) | Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer | |
| CY1126819T1 (el) | Σημασμενοι αναστολεις ειδικου προστατικου αντιγονου μεμβρανης (psma), η χρηση τους ως παραγοντες απεικονισης και φαρμακευτικοι παραγοντες για την αντιμετωπιση του καρκινου του προστατη | |
| CL2017000885A1 (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos | |
| UY36311A (es) | Indazoles sustituidos con bencilo | |
| MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
| AR106243A1 (es) | Inhibidores mejorados del antígeno prostático específico de membrana marcados con 18f y su uso como agentes para la adquisición de imágenes para el cáncer de próstata | |
| TH1801001924A (th) | ตัวยับยั้งที่ถูกแท็กด้วย 18f ที่ถูกปรับปรุงของแอนติเจนที่เมมเบรนจำเพาะต่อต่อมลูก หมาก (psma) และการใช้พวกมันเป็นสารสร้างภาพสำหรับมะเร็งต่อมลูกหมาก |